Positive study data could improve standard of care for Hodgkin lymphoma patients

(Memorial Sloan-Kettering Cancer Center) In a late-stage clinical trial, Hodgkin lymphoma patients who received brentuximab vedotin post-transplant lived longer without disease progression than patients who received only supportive care.